LYZ and cancer: In conclusion, our preliminary investigation suggests that the malignant tumor and the antineoplaston may weaken the patients' oral mucosal immunity, influence the level of some salivary proteins such as SIgA and lysozyme, and result in decreased aggregation of oral bacteria and failure of clearing them from the oral cavity.